Skip to content
lifestyle.serversfree.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ELI LILLY AND COMPANY
Lilly confirms date and conference call for first-quarter 2026 financial results announcement
April 29, 2026
Lilly’s Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
April 28, 2026
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
April 16, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.
April 9, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.
April 9, 2026
FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
April 1, 2026
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
March 31, 2026
Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
March 19, 2026
←
Previous Page
1
…
4
5
6